Results from the investigational, randomized, open-label IRAKLIA phase 3 study demonstrated that Sarclisa administered at a fixed dose subcutaneously (SC) via an on-body delivery system (OBDS) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback